Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 23 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Letermovir tablets in two dosages. The tablets are intended to prevent disease caused by cytomegalovirus in patients who have undergone bone marrow or kidney transplants. The manufacturing will take place at Zydus's facility in Ahmedabad SEZ, India. The press release also notes that Letermovir tablets had significant annual sales in the United States.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases